Navigation Links
Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy

HERSHEY, Pa. and ROCKVILLE, Md., April 24, 2013 /PRNewswire/ -- Immunomic Therapeutics, Inc., ("ITI," Hershey, PA), a leading developer of novel allergy immunotherapies, announced the preliminary results of a Phase I Study to treat individuals with an allergy to Japanese red cedar ("JRC").  The Company is pleased to report that the immunotherapeutic vaccine, JRC-LAMP-vax™, appears to have met all of its primary safety end points.  In addition, preliminary allergic marker results indicate a favorable trend in resolving the allergy.

Within the three subject sub-groups, (24 total patients) there were no reports of any Severe Adverse Events (SAE).  A small number of mild adverse events were reported in about 10% of the vaccinations, generally related to soreness associated with the intra-muscular injection.  The safety results are consistent with other clinical studies that have incorporated LAMP, which also showed the vaccine to be safe and well tolerated.  In addition to monitoring vaccine safety, subjects were also evaluated for immunological markers of allergy including circulating IgE, immunoglobulin G (IgG) and skin test reactivity. 

At the 2013 BIO International Convention, the CEO of Immunomic Therapeutics, Dr. William Hearl , presented the preliminary data for cedar specific IgE and for skin test reactivity.  All patients had stable IgE levels including those patients who entered the study as non-allergic to JRC.  This observation indicates that the vaccine does not induce a new IgE antibody response in either naive or allergic subjects.

Skin testing is perhaps the oldest and most reliable form of allergy testing.  Skin testing has been performed for 100 years and continues to be the test of choice for the diagnosis of allergic disease.  A number of the subjects, both skin test positive and skin test negative at the start of the trial, were found to be skin test negative at the end of the study: 5 of 6 converted from positive to negative for whole JRC extract and all subjects were negative for the specific cedar allergen Cry J2.  In addition, all skin test negative subjects (5) remained skin test negative at the end of the Phase I study.

"Immunomic Therapeutics, Inc., is proud to present these promising results for our first in human Phase I study.  While we are quite excited about the initial skin test results it is important to note that this is a very small number of subjects and we have no indication that the treatment would alleviate the subjects' rhinitis upon exposure to cedar pollen.  Nevertheless, the skin test results are extraordinary in that reversal of a positive result within 132 days of treatment is not usually observed with traditional immunotherapy which may last years and require a 100 or more shots.  To have seen that result within the course of this study gives us – and everyone with an allergy – hope that a solution may be on the horizon."

The Company is planning to continue collecting data for about the next 30 days and will have a more complete report available later this year.  ITI is also planning on initiating a Phase II study of JRC-LAMP-vax later this year and following that in 2014 with our first food allergy immunotherapy for peanut allergy, ARA-LAMP-vax. 

About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company with lab facilities in Rockville, MD and process-development plant in Hershey, PA.  ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases.  For more information about ITI and LAMP Technology please visit


Dr. Bill Hearl, President / CEO

Phone:  1-717-327-1919          

Immunomic Therapeutics, Inc.

1214 Research Blvd, Suite 201

Hershey, PA 17036



SOURCE Immunomic Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
2. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
3. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
4. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
5. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
6. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
7. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
8. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
9. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... N.Y. , Nov. 25, 2015  Henry Schein, ... and services to office-based dental, medical and animal health ... (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion , ... broadest array of open solutions designed to help any ... Click here for a schedule of experts ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for ... of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ ...
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... contact center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term ... fully supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of ...
(Date:11/26/2015)... Ashburn, VA (PRWEB) , ... November 26, 2015 ... ... Planners, an American Express Travel Representative. As a franchise owner, Somu now offers ... range of cruise, destination wedding packages, private cruise sales, as well as, cabin ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, ... in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted ... 8th through Wednesday, November 11th, 2015. The conference was held at the Hawaii ...
Breaking Medicine News(10 mins):